TICAGRELOR AND MAJOR ADVERSE LIMB EVENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)32873-4
Abstract: More potent anti-thrombotic strategies have been shown to reduce major adverse limb events (MALE) in patients with atherosclerosis. Ticagrelor is a potent P2Y12 inhibitor that reduces major adverse cardiovascular events (MACE) in stable patients with… read more here.
Keywords: events systematic; adverse limb; ticagrelor major; limb events ... See more keywords
Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.869804
Abstract: Background: Both sodium glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have cardiovascular protective effects in patients with type 2 diabetes mellitus. However, the comparative risk of GLP-1RA versus SGLT-2i for major… read more here.
Keywords: adverse limb; glp 1ra; limb events; risk ... See more keywords
Predictors for the Development of Major Adverse Limb Events after Percutaneous Revascularization—Gender-Related Characteristics
Sign Up to like & getrecommendations! Published in 2023 at "Medicina"
DOI: 10.3390/medicina59030480
Abstract: Background and Objectives: Revascularization has been proven to be superior to medication for symptom improvement in patients with peripheral arterial disease (PAD). There are well known gender differences in therapeutic strategies for PAD. The influence… read more here.
Keywords: limb; adverse limb; limb events; major adverse ... See more keywords